Comparative Effectiveness of Ozanimod and Vedolizumab as First-Line Advanced Therapies in Ulcerative Colitis: A Propensity-Matched Cohort Analysis

Journal article

Open access

Peer reviewed

Gursimran S. Kochhar, Himsikhar Khataniar, Jana G. Hashash, Fjona Tabaku, Miguel Regueiro, Francis A. Farraye and Aakash Desai

Inflammatory bowel diseases, v 31(7), pp 1868-1875

01 Jul 2025

PMID: 39478367

Files and links (1)

url

https://doi.org/10.1093/ibd/izae251View

Published, Version of Record (VoR) Open

Gastroenterology & Hepatology

Life Sciences & Biomedicine

Science & Technology

Ozanimod use is associated with similar outcomes compared to vedolizumab when used as first-line therapy in patients with ulcerative colitis.

5 Record Views

Title: Comparative Effectiveness of Ozanimod and Vedolizumab as First-Line Advanced Therapies in Ulcerative Colitis: A Propensity-Matched Cohort Analysis
Creators: Gursimran S. Kochhar - Allegheny Hlth Network, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA USA
Himsikhar Khataniar - Allegheny Hlth Network, Dept Internal Med, Pittsburgh, PA USA
Jana G. Hashash - Mayo Clin, Div Gastroenterol & Hepatol, Jacksonville, FL USA
Fjona Tabaku - Allegheny Hlth Network, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA USA
Miguel Regueiro - Cleveland Clin Fdn, Div Gastroenterol & Hepatol, Cleveland, OH USA
Francis A. Farraye - Mayo Clin, Div Gastroenterol & Hepatol, Jacksonville, FL USA
Aakash Desai (Corresponding Author) - Allegheny Hlth Network, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA USA
Publication Details: Inflammatory bowel diseases, v 31(7), pp 1868-1875
Publisher: Oxford University Press
Number of pages: 8
Resource Type: Journal article
Language: English
Academic Unit: General Internal Medicine
Web of Science ID: WOS:001345031000001
Scopus ID: 2-s2.0-105010254883
Other Identifier: 991022135679604721

This publication has contributed to the advancement of the following goals:

Data related to this publication, from InCites Benchmarking & Analytics tool: